PHASE 1 TRIAL WITH CONTROLLED HUMAN MALARIA INFECTION: AN OPEN LABEL DOSE-ESCALATION SAFETY, REACTOGENICITY, IMMUNOGENICITY, AND EFFICACY STUDY OF THE CANDIDATE VACCINE PLASMODIUM FALCIPARUM MALARIA PROTEIN (FMP012), AN E-COLI-EXPRESSED CELL-TRAVERSAL PROTEIN FOR OOKINETES AND SPOROZOITES (PFCELTOS), ADMINISTERED INTRAMUSCULARLY WITH THE ADJUVANT SYSTEM AS01(B) IN HEALTHY, MALARIA-NAIVE ADULTS